adjuvant radiation is not associated with improved survival in patients with positive margins...
Post on 18-Jan-2016
214 Views
Preview:
TRANSCRIPT
Adjuvant Radiation is Not Associated with Improved Survival in Patients with Positive Margins Following
Lobectomy for Stage I & II Non-Small Cell Lung Cancer
Brian C Gulack, MD; Jeffrey Chi-Fu Yang, MD; Paul J Speicher, MD, MHS; H. Volkan Kara, MD; Thomas A D’Amico, MD; Mark F Berry, MD,
MHS; Matthew G Hartwig, MD
1
Disclosures
• Dr. Thomas D’Amico serves as a consultant for Scanlan.• The other authors have no conflicts of interest to report.
• The National Cancer Data Base is a joint project of the Commission on Cancer of the American College of Surgeons and the American Cancer Society.
• The COC and the ACS are not responsible for the analytic or statistical methodology employed, or the conclusions drawn from these data.
2
Background
• Lobectomy– Most common surgical procedure performed for stage I or
II NSCLC.– 4-6% associated with positive margins.
• Current NCCN guidelines for positive margins:– Re-resection +/- chemotherapy (preferred).– Adjuvant radiation +/- chemotherapy.– Based on limited data.
• Reviewed the National Cancer Data Base (NCDB) in order to better guide therapy for this clinical scenario.– Hypothesis: Significant benefit from adjuvant XRT
3
Methods
• National Cancer Data Base– Collects information from over 1500 Commission-on-
Cancer accredited hospitals.– Captures roughly 70% of newly diagnosed cancers in the
United States each year.
4
Methods
Inclusion Criteria:• Lobectomy or Pneumonectomy for Clinical Stage I
or II NSCLC from 1998-2006.
Exclusion Criteria:• Unknown follow-up.• Known neoadjuvant therapy.• Patient receiving a lobectomy who died within 30
days of surgery.
5
6
Lobectomy for Stage I or II NSCLC
Negative Margins Positive Margins
Included: -R1 Disease -R2 Disease -Positive Margins NOS
Methods
7
Lobectomy for Stage I or II NSCLC
Negative Margins Positive Margins
Methods
Adjuvant Radiation
No Adjuvant Radiation
8
Lobectomy for Stage I or II NSCLC
Negative Margins Positive Margins
Adjuvant Radiation
No Adjuvant Radiation
Adjuvant Radiation Pneumonectomy
Propensity Match
Methods
Results
9
VariableNegative Margins Positive Margins P-value
N 48051 (96.1%) 1959 (3.9%) Age (years) 68 (61, 74) 68 (61, 75) 0.28 Female Sex 50.2% 45.9% < 0.01 Race <0.01 White 90.1% 87.8% Black 7.0% 9.1% Other/Unknown 2.9% 3.1% Private Insurance Status 35.3% 34.6% 0.55 Academic Center 33.8% 27.5% < 0.01
Results
10
VariableNegative Margins Positive Margins P-value
N 48051 (96.1%) 1959 (3.9%) Age (years) 68 (61, 74) 68 (61, 75) 0.28 Female Sex 50.2% 45.9% < 0.01 Race <0.01 White 90.1% 87.8% Black 7.0% 9.1% Other/Unknown 2.9% 3.1% Private Insurance Status 35.3% 34.6% 0.55 Academic Center 33.8% 27.5% < 0.01
Results
10
VariableNegative Margins Positive Margins P-value
N 48051 (96.1%) 1959 (3.9%) Age (years) 68 (61, 74) 68 (61, 75) 0.28 Female Sex 50.2% 45.9% < 0.01 Race <0.01 White 90.1% 87.8% Black 7.0% 9.1% Other/Unknown 2.9% 3.1% Private Insurance Status 35.3% 34.6% 0.55 Academic Center 33.8% 27.5% < 0.01
Results
11
VariableNegative Margins Positive Margins P-value
N 48051 (96.1%) 1959 (3.9%)Tumor Size > 5.0 cm 11.8% 21.7% < 0.01Clinical Stage II 10.5% 28.7% <0.01
Results
11
VariableNegative Margins Positive Margins P-value
N 48051 (96.1%) 1959 (3.9%)Tumor Size > 5.0 cm 11.8% 21.7% < 0.01Clinical Stage II 10.5% 28.7% <0.01
Results
11
VariableNegative Margins Positive Margins P-value
N 48051 (96.1%) 1959 (3.9%)Tumor Size > 5.0 cm 11.8% 21.7% < 0.01Clinical Stage II 10.5% 28.7% <0.01
Results
Negative Margin
34.5%
P < 0.001
57.2%
Positive Margin
Adjusted HR: 1.46 (95% CI: 1.33, 1.60)
Covariates included in adjustment: age, sex, race, insurance status, Charlson/Deyo comorbidity index, pathologic grade, pathologic stage.
Results
13
Variable No Adjuvant Radiation
Adjuvant Radiation p-value
N 949 (61.8%) 587 (38.2%)Age 70 (62, 76) 67 (60, 73) < 0.001Female 47.0% 41.6% 0.043Academic Center 30.9% 19.6% < 0.001Tumor Size > 5.0 cm 19.0% 27.5% < 0.001Clinical Stage II 20.4% 37.5% < 0.001Pathologic Stage II 36.4% 61.4% < 0.001Adjuvant Chemotherapy 27.3% 57.1% < 0.001
Results
13
Variable No Adjuvant Radiation
Adjuvant Radiation p-value
N 949 (61.8%) 587 (38.2%)Age 70 (62, 76) 67 (60, 73) < 0.001Female 47.0% 41.6% 0.043Academic Center 30.9% 19.6% < 0.001Tumor Size > 5.0 cm 19.0% 27.5% < 0.001Clinical Stage II 20.4% 37.5% < 0.001Pathologic Stage II 36.4% 61.4% < 0.001Adjuvant Chemotherapy 27.3% 57.1% < 0.001
Results
13
Variable No Adjuvant Radiation
Adjuvant Radiation p-value
N 949 (61.8%) 587 (38.2%)Age 70 (62, 76) 67 (60, 73) < 0.001Female 47.0% 41.6% 0.043Academic Center 30.9% 19.6% < 0.001Tumor Size > 5.0 cm 19.0% 27.5% < 0.001Clinical Stage II 20.4% 37.5% < 0.001Pathologic Stage II 36.4% 61.4% < 0.001Adjuvant Chemotherapy 27.3% 57.1% < 0.001
Results
13
Variable No Adjuvant Radiation
Adjuvant Radiation p-value
N 949 (61.8%) 587 (38.2%)Age 70 (62, 76) 67 (60, 73) < 0.001Female 47.0% 41.6% 0.043Academic Center 30.9% 19.6% < 0.001Tumor Size > 5.0 cm 19.0% 27.5% < 0.001Clinical Stage II 20.4% 37.5% < 0.001Pathologic Stage II 36.4% 61.4% < 0.001Adjuvant Chemotherapy 27.3% 57.1% < 0.001
Results
13
Variable No Adjuvant Radiation
Adjuvant Radiation p-value
N 949 (61.8%) 587 (38.2%)Age 70 (62, 76) 67 (60, 73) < 0.001Female 47.0% 41.6% 0.043Academic Center 30.9% 19.6% < 0.001Tumor Size > 5.0 cm 19.0% 27.5% < 0.001Clinical Stage II 20.4% 37.5% < 0.001Pathologic Stage II 36.4% 61.4% < 0.001Adjuvant Chemotherapy 27.3% 57.1% < 0.001
Results
13
Variable No Adjuvant Radiation
Adjuvant Radiation p-value
N 949 (61.8%) 587 (38.2%)Age 70 (62, 76) 67 (60, 73) < 0.001Female 47.0% 41.6% 0.043Academic Center 30.9% 19.6% < 0.001Tumor Size > 5.0 cm 19.0% 27.5% < 0.001Clinical Stage II 20.4% 37.5% < 0.001Pathologic Stage II 36.4% 61.4% < 0.001Adjuvant Chemotherapy 27.3% 57.1% < 0.001
No significant differences in insurance status, or Charlson/Deyo Comorbidity Index.
Results
No Adjuvant Radiation
P = 0.009
Adjuvant Radiation
Adjusted HR: 1.08 (95% CI: 0.88, 1.32)
Covariates included in adjustment: age, sex, race, insurance status, Charlson/Deyo comorbidity index, pathologic grade, pathologic stage.
Results
15
Variable Pneumonectomy Lobectomy p-value
N 450 225
Age 68 (59.2, 74) 67 (60, 74) 0.85
Female 42.4% 42.2% 0.99
Charlson/Deyo Comorbidity Index
0.96
0 56.9% 57.8%
1 32.7% 31.6%
2 10.4% 10.7%
Tumor Size > 5.0 cm 21.8% 21.8% 0.99
Pathologic Stage II 57.6% 59.1% 0.79
Results
16
Pneumonectomy
Lobectomy w/XRT
Results
16
Pneumonectomy
Lobectomy w/XRT
Pneumonectomy vs LobectomyHR: 0.96, 95% CI: 0.77, 1.20
Results
16
Pneumonectomy
Lobectomy w/XRTPneumonectomy vs LobectomyHR: 0.73, 95% CI: 0.60, 0.89
Results
16
Pneumonectomy
Lobectomy w/XRT
Pneumonectomy vs Lobectomy5-Year: HR: 0.50, 95% CI: 0.38, 0.66
45.3%
33.7%
Limitations
– Potential for unobserved confounding.• Details of treatment decisions regarding adjuvant therapy
and deferring re-resection not available.
– Radiation therapy for other indications.
– Limited ability to assess the impact of adjuvant chemotherapy.
18
Summary
– Lobectomy for Stage I or II NSCLC is associated with a 4% positive margin rate.
– Positive margins are associated with reduced survival.
– Adjuvant Radiation therapy is not associated with a significant survival benefit.
– Re-resection, when feasible, may be a superior treatment option.
17
top related